Sino Medical Sciences Technology Inc. (SHA:688108)
China · Delayed Price · Currency is CNY 22.27
+0.06 (0.27%)
At close: Feb 13, 2026
SHA:688108 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 503.31 | 457.94 | 340.02 | 192.58 | 194.1 | 326.25 |
Other Revenue | 0.8 | 0.8 | 3.23 | 0.27 | 0.26 | 1.17 |
| 504.11 | 458.74 | 343.26 | 192.85 | 194.36 | 327.42 | |
Revenue Growth (YoY) | 20.85% | 33.64% | 77.99% | -0.77% | -40.64% | -24.89% |
Cost of Revenue | 194.15 | 192.64 | 145.64 | 85.64 | 60.25 | 67.1 |
Gross Profit | 309.96 | 266.1 | 197.62 | 107.21 | 134.11 | 260.32 |
Selling, General & Admin | 171.69 | 168.45 | 157.77 | 174.76 | 150.02 | 138.04 |
Research & Development | 126.91 | 140.56 | 114.1 | 152.8 | 148.93 | 108.73 |
Other Operating Expenses | -4.56 | -7.5 | 2.15 | 0.77 | 1.8 | 1.16 |
Operating Expenses | 293.65 | 301.08 | 272.61 | 329.66 | 300.21 | 248.42 |
Operating Income | 16.3 | -34.98 | -74.99 | -222.45 | -166.1 | 11.9 |
Interest Expense | -5.28 | -5.61 | -3.75 | -2.55 | -2.2 | - |
Interest & Investment Income | 2.42 | 13.62 | 2.63 | 2.98 | 4.68 | 12.98 |
Currency Exchange Gain (Loss) | -0.19 | -0.19 | -1.01 | 0.52 | -0.57 | -0.78 |
Other Non Operating Income (Expenses) | 0.61 | -0.22 | -0.18 | -0.17 | -0.16 | 4.58 |
EBT Excluding Unusual Items | 13.86 | -27.39 | -77.3 | -221.67 | -164.36 | 28.68 |
Gain (Loss) on Sale of Investments | - | - | -4.67 | -4.11 | -0.29 | - |
Gain (Loss) on Sale of Assets | 0.2 | 0.2 | -1.55 | -2.21 | 0.11 | 0.01 |
Asset Writedown | 8.99 | - | - | - | - | -0.02 |
Other Unusual Items | 10.03 | 10.03 | 15.66 | 6.65 | 1.43 | 0.18 |
Pretax Income | 33.08 | -17.16 | -67.86 | -221.34 | -163.1 | 28.84 |
Income Tax Expense | 1.32 | -13.27 | -24.46 | -48.03 | -31.8 | 6.35 |
Earnings From Continuing Operations | 31.76 | -3.89 | -43.4 | -173.31 | -131.3 | 22.49 |
Minority Interest in Earnings | 1.77 | 5.39 | 3.77 | 10.93 | 0.53 | - |
Net Income | 33.53 | 1.5 | -39.63 | -162.38 | -130.77 | 22.49 |
Net Income to Common | 33.53 | 1.5 | -39.63 | -162.38 | -130.77 | 22.49 |
Net Income Growth | - | - | - | - | - | -75.02% |
Shares Outstanding (Basic) | 418 | 374 | 396 | 406 | 409 | 410 |
Shares Outstanding (Diluted) | 418 | 374 | 396 | 406 | 409 | 410 |
Shares Change (YoY) | 17.47% | -5.51% | -2.38% | -0.66% | -0.33% | 9.29% |
EPS (Basic) | 0.08 | 0.00 | -0.10 | -0.40 | -0.32 | 0.05 |
EPS (Diluted) | 0.08 | 0.00 | -0.10 | -0.40 | -0.32 | 0.05 |
EPS Growth | - | - | - | - | - | -79.17% |
Free Cash Flow | 116.18 | 61.22 | -10.83 | -222.07 | -218.58 | -42.27 |
Free Cash Flow Per Share | 0.28 | 0.16 | -0.03 | -0.55 | -0.54 | -0.10 |
Gross Margin | 61.49% | 58.01% | 57.57% | 55.59% | 69.00% | 79.51% |
Operating Margin | 3.23% | -7.63% | -21.84% | -115.35% | -85.46% | 3.64% |
Profit Margin | 6.65% | 0.33% | -11.54% | -84.20% | -67.28% | 6.87% |
Free Cash Flow Margin | 23.05% | 13.35% | -3.16% | -115.15% | -112.46% | -12.91% |
EBITDA | 91.15 | 29.61 | -24.07 | -172.09 | -113.86 | 50.21 |
EBITDA Margin | 18.08% | 6.46% | -7.01% | -89.23% | -58.58% | 15.33% |
D&A For EBITDA | 74.85 | 64.59 | 50.92 | 50.36 | 52.24 | 38.3 |
EBIT | 16.3 | -34.98 | -74.99 | -222.45 | -166.1 | 11.9 |
EBIT Margin | 3.23% | -7.63% | -21.84% | -115.35% | -85.46% | 3.64% |
Effective Tax Rate | 3.99% | - | - | - | - | 22.01% |
Revenue as Reported | 504.11 | 458.74 | 343.26 | 192.85 | 194.36 | 327.42 |
Advertising Expenses | - | 1.7 | 1.13 | 2.45 | - | 10.21 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.